BioMed X institute and Merck KGaA extend cancer collaboration

1 February 2022

German independent research institute BioMed X says it has extended its collaboration with Merck KGaA (MRK: DE) in the research project RNA Splicing in Cancer (RSC).

As a result of the successful research work to date, Merck has decided to acquire the intellectual property (IP) rights in the project results and to continue the project for another year.

The goal of the extension is to further validate novel potential drug targets based on these results. This research program marks the partners’ fifth joint project in oncology and is already the second program to be extended beyond the originally anticipated four-year timeframe. Since the inception of the BioMed X Institute in 2013, Merck has initiated and supported a total of eight different research groups at BioMed X, also in the fields of immuno-oncology, and autoimmunity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK